Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Common Equity (2016 - 2025)

Historic Common Equity for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q4 2025 value amounting to $1.2 billion.

  • Agios Pharmaceuticals' Common Equity fell 2257.31% to $1.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.2 billion, marking a year-over-year decrease of 2257.31%. This contributed to the annual value of $1.2 billion for FY2025, which is 2257.31% down from last year.
  • Per Agios Pharmaceuticals' latest filing, its Common Equity stood at $1.2 billion for Q4 2025, which was down 2257.31% from $1.3 billion recorded in Q3 2025.
  • Agios Pharmaceuticals' Common Equity's 5-year high stood at $2.3 billion during Q1 2021, with a 5-year trough of $660.5 million in Q2 2024.
  • Moreover, its 5-year median value for Common Equity was $1.2 billion (2022), whereas its average is $1.2 billion.
  • As far as peak fluctuations go, Agios Pharmaceuticals' Common Equity surged by 26728.51% in 2021, and later plummeted by 4742.5% in 2022.
  • Agios Pharmaceuticals' Common Equity (Quarter) stood at $1.3 billion in 2021, then dropped by 14.8% to $1.1 billion in 2022, then fell by 26.33% to $811.0 million in 2023, then surged by 90.0% to $1.5 billion in 2024, then dropped by 22.57% to $1.2 billion in 2025.
  • Its Common Equity was $1.2 billion in Q4 2025, compared to $1.3 billion in Q3 2025 and $1.4 billion in Q2 2025.